Image: StockTitanSoligenix Advances Phase 3 Trials for HyBryte in Cutaneous T-Cell Lymphoma Treatment
• Soligenix's HyBryte for cutaneous T-cell lymphoma (CTCL) has a second Phase 3 trial underway with enrollment of approximately 80 subjects, interim analysis in Q2 2026, and top-line results in H2 2026. • Previous Phase 3 trials showed statistical significance in primary endpoints across multiple cycles, following FDA NDA submission and RTF letter. • The program targets unmet needs in rare dermatological cancers with ongoing FDA discussions for development path.
stocktitan.net